具有pH依赖释放的聚合物纳米载体用于瘤特异性输送
Chintan Aundhia1, Ghanshyam Parmar1, Chitrali Talele1
1Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara-391760, Gujarat, India.
Recent advances in drug delivery and formulation
|August 24, 2025
概括
响应pH的聚合物纳米载体利用酸性瘤微环境进行向药物输送. 这些智能系统增强了瘤部位的治疗积累,最大限度地减少了副作用,改善了治疗结果.
科学领域:
- 生物医学工程
- 纳米技术
- 癌症学
背景情况:
- 瘤微环境的特点是酸性pH值.
- 这种酸度为向药物输送提供了机会.
- 常规疗法往往会产生系统性副作用.
研究的目的:
- 为瘤向药物输送提供pH响应的聚合物纳米载体的全面审查.
- 讨论设计原则,制造和应用.
- 探索临床潜力和挑战.
主要方法:
- 对pH响应纳米载体的现有文献的审查.
- 对pH触发药物释放机制的分析.
- 讨论聚合物工程对于pH敏感性的策略.
主要成果:
- 响应pH的纳米载体可以设计在酸性瘤环境中选择性释放药物.
- 这些系统增强了瘤中的药物积累.
- 系统性毒性降低是一个关键的好处.
结论:
- 响应pH的聚合物纳米载体为改善癌症治疗提供了有前途的策略.
- 需要进一步的研究和临床转化来克服现有的挑战.
- 开发瘤酸性是推进向药物输送的关键.
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160


